Similar Papers

Paper Title
Journal
Date
Author
Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study
Efstathios Kastritis ... Meletios A Dimopoulos
Blood | VOL. 138
Efstathios Kastritis, et. al.Efstathios Kastritis ... Meletios A Dimopoulos
05 Nov 2021
Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study
...
Blood | VOL. 134
, et. al. ...
13 Nov 2019
LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy
Philippe Moreau ...
Blood | VOL. 138
Philippe Moreau, et. al.Philippe Moreau ...
05 Nov 2021
Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Alex F Herrera ... Stephen M Ansell
Blood | VOL. 136
Alex F Herrera, et. al.Alex F Herrera ... Stephen M Ansell
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
The JAK2 46/1 haplotype influences PD-L1 expression.
Gonzalo Carreño-Tarragona ... Miguel Manzanares
Blood | VOL. -
Gonzalo Carreño-Tarragona, et. al.Gonzalo Carreño-Tarragona ... Miguel Manzanares
07 Feb 2025
Targeting cell surface VISTA expression on allospecific naïve T cells promotes tolerance.
Brent H Koehn ... Bruce R Blazar
Blood | VOL. -
Brent H Koehn, et. al.Brent H Koehn ... Bruce R Blazar
07 Feb 2025
Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study.
Ioannis Mantzaris ... Eric J Feldman
Blood | VOL. -
Ioannis Mantzaris, et. al.Ioannis Mantzaris ... Eric J Feldman
07 Feb 2025
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements.
Qiudan Shen ... Shimin Hu
Blood | VOL. 145
Qiudan Shen, et. al.Qiudan Shen ... Shimin Hu
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.